Innoviva - 8 Year Stock Split History | INVA

Stock split history for Innoviva since 2016. Prices shown are actual historical values and are not adjusted for either splits or dividends. Please see the "Historical Prices" tab for adjusted price values.
Innoviva Annual Stock Splits
Innoviva Quarterly Stock Splits
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.073B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $814.944B 117.78
Novo Nordisk (NVO) Denmark $590.290B 45.36
Johnson & Johnson (JNJ) United States $372.289B 14.76
Merck (MRK) United States $318.551B 57.96
AbbVie (ABBV) United States $304.294B 15.72
AstraZeneca (AZN) United Kingdom $244.043B 21.22
Novartis AG (NVS) Switzerland $216.930B 15.08
Pfizer (PFE) United States $169.828B 21.11
Sanofi (SNY) $128.207B 12.08